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Abstract
Background: There are a number of different manifestations of pulmonary aspergillosis. This study aims to review
the radiology, presentation, and histological features of lung nodules caused by Aspergillus spp.
Methods: Patients were identified from a cohort attending our specialist Chronic Pulmonary Aspergillosis clinic.
Patients with cavitating lung lesions, with or without fibrosis and those with aspergillomas or a diagnosis of
invasive aspergillosis were excluded. Demographic, laboratory, and clinical data and radiologic findings were
recorded.
Results: Thirty-three patients with pulmonary nodules and diagnostic features of aspergillosis (histology and/or
laboratory findings) were identified. Eighteen (54.5 %) were male, mean age 58 years (range 27–80 years). 19 (57.6 %)
were former or current smokers. The median Charleston co-morbidity index was 3 (range 0–7). All complained of a
least one of; dyspnoea, cough, haemoptysis, or weight loss. None reported fever. Ten patients (31 %) did not have an
elevated Aspergillus IgG, and only 4 patients had elevated Aspergillus precipitins. Twelve patients (36 %) had a single
nodule, six patients (18 %) had between 2 and 5 nodules, 2 (6 %) between 6 and 10 nodules and 13 (39 %) had more
than 10 nodules. The mean size of the nodules was 21 mm, with a maximum size ranging between 5–50 mm. No
nodules had cavitation radiographically. The upper lobes were most commonly involved. Histology was available for 18
patients and showed evidence of granulation tissue, fibrosis, and visualisation of fungal hyphae.
Conclusion: Pulmonary nodules are a less common manifestation of aspergillosis in immunocompetent patients.
Distinguishing these nodules from other lung pathology may be difficult on CT findings alone.
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Background
There are a number of manifestations of pulmonary as-
pergillosis [1]. Aspergillus spp. are ubiquitous in the en-
vironment and exposure to conidia is common.
However, only a minority of people develop clinical dis-
ease, and this is often determined by host characteristics,
e.g. immune compromise, genetic predisposition, under-
lying lung pathology, and prior pulmonary infection
such as tuberculosis (TB). Classically chronic pulmonary
aspergillosis (CPA) in immunocompetent patients pre-
sents as a saprophytic infection in a pre-existing cavity,
often following an infection such as TB or prior lung
surgery. There are a number of recognised manifesta-
tions of CPA; subacute invasive pulmonary aspergillosis
(SAIA) [which may be referred to as chronic necrotising
pulmonary aspergillosis (CNPA)], chronic cavitary
pulmonary aspergillosis (CCPA) and chronic fibrosing
pulmonary aspergillosis (CFPA) [2]. Subacute IPA occurs
in the setting of some degree of immune compromise,
and may present with nodules, consolidation and or
cavitation on chest imaging, and a more rapidly progres-
sive clinical course. CCPA presents with single or mul-
tiple cavities, with or without aspergilloma(s), and CFPA
has this appearance with the additive features of
pulmonary fibrosis, which may be progressive and
destructive.
Estimates of the incidence and prevalence of CPA are
difficult; however the global burden of disease is
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increasingly being recognised [3, 4]. For example, the
proportion of patients with TB as an underlying risk fac-
tor for the development of CPA will vary depending on
geographical location [5]. In 2011, CPA was estimated to
affect 3600 patients in the UK, based on estimates of
prior TB, and diagnoses of sarcoidosis [6], and 1.2 mil-
lion worldwide after TB [3] and 72,000 complicating
fibrocystic pulmonary sarcoidosis [4].
There is a paucity of knowledge on CPA which presents
as single or multiple nodule(s) without cavitation in im-
mune competent hosts. The published literature is limited
to case reports and small case series. Often, in these cases
the diagnosis is made following removal or biopsy of the
nodule(s) which is presumed to be malignant [7, 8]. In the
largest case series from Korea, eleven patients with solitary
pulmonary nodules were reviewed [9]. Three of the eleven
patients had some evidence of cavitation on CT imaging,
and all had histologically proven Aspergillus infection. In a
second Korean series, seven patients were identified with
biopsy proven Aspergillus disease, in the absence of im-
munosuppression or underlying lung disease [10]. Unfor-
tunately in neither series was a correlation made with
Aspergillus IgG (precipitins), which is a cornerstone of the
diagnosis of CPA [2].
The purpose of this study is to review the clinical
characteristics, histological and radiological features of
pulmonary nodules caused by Aspergillus spp.
Methods
Patients attending our specialist CPA clinic in the
National Aspergillosis Centre (NAC) with nodular
Aspergillus disease were identified. The NAC is
nationally commissioned to provide specialist care for
patients with chronic pulmonary aspergillosis in the
UK. There are currently approximately 350 patients
in follow up care of the NAC with CPA, and
approximately 100 new patients referred annually.
Patients were identified by one of two methods. First,
patients with pulmonary nodules on chest imaging at
presentation, and features consistent with a diagnosis
of aspergillosis (i.e. biopsy proven disease and/or
positive Aspergillus serology and/or Aspergillus spp
isolated form respiratory secretions) were prospect-
ively recorded. Second, additional case finding was
performed by the retrospective review of patient cor-
respondence and review of histopathology records. A
rounded opacity, well or poorly defined, measuring
up to 3 cm in diameter was defined as a nodule as
per the Fleischner Society: Glossary of Terms for
Thoracic Imaging [11]. Patients with aspergillomas
and those with cavitating lung lesions, with or with-
out fibrosis were excluded. Patients with a diagnosis
of invasive aspergillosis were also excluded. Demo-
graphic data, details of the clinical presentation,
laboratory data and radiologic findings were recorded
on each patient. All radiology was reviewed by a
consultant radiologist (AS) for accuracy. The Immu-
noCap™ assay (Phadia, Uppsala, Sweden) was used to
measure A. fumigatus IgG and the Microgen antigens
and counterimmunoelctrophoresis (MIcrogen, Camberley,
Surrey, UK) for Aspergillus precipitins. Serum mannose
binding lectin (MBL) concentrations were measured by
ELISA (MBL Oligomer ELISA Kit, BioPorto Diagnostics,
DK), upper and lower reported detection limit of 4.00 and
0.05 mg/L respectively. For culture, sputum was digested
with Sputasol® (ratio 1:1), vortexed, and 10 μL-streaked on
two Sabouraud dextrose agar plates [12] and incubated at
30 °C and 37 °C for 7 days, and on bacterial media. For
quantitative PCR, the MycXtra kit (Myconostica,
Cambridge, UK) was used for DNA extraction using 0.5–
3 mL of sample. DNA was eluted in 40 μL and 10 μL used
for quantitative PCR. The MycAssay Aspergillus kit
(Myconostica) was used following the manufacturer’s in-
structions; a crossing threshold (Ct) of >38 was negative,
Ct from 36–38 a weak positive and <36 was interpreted as
a strong positive [13]. The data were collected in Micro-
soft excel, and data analysis performed using SPSS version
20. This report is a retrospective evaluation of all patients
who were managed with Aspergillus nodules, and as such
is exempt from ethical review or patient consent.
Results
Thirty three patients with lung nodules and features
diagnostic of CPA (histology and/or laboratory findings)
were identified. Ten patients had proven disease, and
the remainder deemed probable disease, based on ser-
ology and culture results (Table 1). Eighteen (54.5 %) of
patients were male, the mean age was 58 years (range
27–80 years). Nineteen (57.6 %) were current or ex-
smokers, in 9 (27.3 %) smoking history was not docu-
mented. The median Charleston co-morbidity index was
3 (range 0–7). On presentation all patients complained
of a least one of the following symptoms; dyspnoea,
cough, haemoptysis, or weight loss. Twenty nine patients
(88 %) reported cough, 23 (70 %) dyspnoea, 11 (33 %)
described weight loss, and 5 (15 %) haemoptysis. No
patients reported a history of fever.
Radiological features
All patients had computer tomography (CT) performed.
Twenty patients (60 %) had upper lobe disease alone,
with either unilateral or bilateral involvement. In seven
patients (6 %) all lobes were involved, the remaining
patients had variable patterns of lobar involvement. In
twelve patients (36 %) a single nodule was present, six
(18 %) patients had between 2 and 5 nodules, 2 (6 %)
had between 6 and 10 nodules and 13 (39 %) patients
more than 10 nodules. The maximum nodule size
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1 1 LLL 11 N Y None 76 n/a lung fibrosis, fungal hyphae
2 2 Upper lobes
bilaterally
4 10 n y None 68 Negative lung granuloma, necrosis,
fungal hyphae
3 1 LUL 16 n y Dyspnoea, cough,
weight loss
14 Negative lung Inflammation, fungal
hyphae
4 2 RUL 7 n y Cough, weight loss 40 Negative Lung Inflammation
granulomatous
5 1 RUL 16 n y Dyspnoea, weight loss 101 n/a lung COP, fungal hyphae
6 1 RUL 12 n y Dyspnoea, cough,
haemoptysis
N/A A. fumigatus n/a BAL inflammatory infiltrate
fungal hyphae
7 1 LUL 22 n y Dyspnoea, cough 22 N/A lung fibrosis, granulomata,
necrosis, fungal hyphae
8 1 RUL 22 n y Dyspnoea, cough,
haemoptysis
86 Negative lung Inflammation, fungal
hyphae
9 3 Upper lobes
bilaterally
6 27 n y Dyspnoea, cough,
weight loss
54 A. fumigatus Negative lung fungal hyphae, necrosis
10 1 LLL 25 could not
visualise
y Dyspnoea, cough 23 A. fumigatus Positive Lung Inflammation
granulomatous





12 4 All lobes 2 38 y y Dyspnoea, cough,
haemoptysis
185 Positive
13 2 Upper lobes
bilaterally
3 9 n N/A Cough 87 Negative
14 4 All lobes
except RUL
2 16 n y Dyspnoea, cough 49 n/a BAL benign cells,
polymorphs
15 2 Upper lobes
bilaterally
7 12 y y Dyspnoea, cough 68 Negative
16 4 all lobes
except RML
5 16 n Y Dyspnoea, cough 65 A. nidulans,
A. niger
Negative
17 1 LUL 14 n Y Dyspnoea, cough,
weight loss
152 N/A BAL benign cells,
polymorphs
18 1 RUL 10 n y Cough, weight loss 18 n/a
19 4 All lobes 2 31 Y Y Dyspnoea, cough,
haemoptysis, weight
loss




20 4 Upper lobes
bilaterally

















Table 1 Characteristic of patients diagnosed with Aspergillus nodule(s) (Continued)
21 4 All lobes
except RUL
1 18 n y Dyspnoea, cough 115 A fumigatus Positive







23 4 All lobes 1 16 y n Dyspnoea, cough 75 N/A Lung Emphysema bullous
24 1 RUL 20 n y Cough 12 A.
fumigatuis
N/A
25 4 All lobes 1 20 y Y Cough 170 Negative




27 4 All lobes 1 5 n y Dyspnoea, cough 42 A. fumigatus Positive
28 4 RUL 1 27 n y Cough, haemoptysis 82 Positive
29 4 all except
RML, RLL
1 28 N Y Dyspnoea 42.5 N/A
30 3 LUL 5 37 n y Cough 106 Negative
31 1 RUL 29 n y Cough 18 Negative
32 4 All lobes 6 32 n y Dyspnoea, cough,
weight loss
10 N/A

















ranged between 5–50 mm, mean 21 mm. Associated
lymphadenopathy was present in six patients (18 %).
Thirty patients had a plain chest film performed concur-
rently with the CT imaging, in 29/30 (97 %) the nodule
was visible on plain film. Eight patients (24 %) had
undergone positron emission tomography (PET) and in
all cases the fluorodeoxyglucose (FDG) uptake was low
to moderate (SVUmax <5.4). Twenty three patients
(70 %) had a solid mass on CT imaging (Fig. 1), while
the remaining patients had a mixed pattern of disease.
Eleven patients had findings consistent with emphysema
on CT imaging. One patient initially had a cavitating le-
sion which became solid on repeat imaging (Fig. 2). Only
one patient, with multiple nodules, had evidence of cal-
cification within some nodules.
Laboratory parameters
Aspergillus IgG antibody results were available for 32
patients. In ten patients (31 %) the Aspergillus IgG was
within normal limits (i.e. ≤40 mg/L), including four
patients with a result between 20 mg/L and 40 mg/L.
Aspergillus precipitins was positive in 4/32 (12.5 %).
Eight patients (24 %) had lymphopenia (lymphocyte
count <1.5 × 109/L). Twenty nine patients had MBL
measured, and 11/29 (38 %) were deficient (<1.0 mg/L).
Twenty nine patients submitted sputum samples for
analysis. Nine of the 32 patients (31 %) isolated an A.
Fig. 1 Different patterns of Aspergillus nodule disease. A showing
multiple nodules, B a single pulmonary nodule on background of
emphysematous lungs
Fig. 2 CT imaging showing cavitating disease initially, which
developed into nodular disease
Muldoon et al. BMC Pulmonary Medicine  (2016) 16:123 Page 5 of 9
fumigatus from their sputum sample, one of whom also
had A. nidulans isolated from their sputum. One patient
had A. nidulans and A. niger isolated from his sputum
samples. Sputum samples also yielded a number of bac-
terial organisms including S. aureus, H. influenzae, H.
parainfluenzae, M. catarrhalis, S. marcescens, E. coli, K.
pneumoniae, S. maltophilia, and P. aeruginosa. Seven
patients had sputum samples which did not yield any
growth of bacteria or fungi. Twenty two patients submit-
ted sputum for Aspergillus PCR analysis, 10/22 (45 %)
were positive. In four cases (4/14) Aspergillus DNA was
detected by PCR but there was no growth of Aspergillus
spp. by culture.
Histology
Histology was available on sixteen patients. Thirteen
(81 %) had undergone lung biopsy, and the remainder
had bronchoalveolar lavage (BAL) fluid analysed. Of
those who had undergone lung biopsy, in 7/13 (54 %)
fungal hyphae were visualised. Granulomatous inflam-
mation and/ or necrosis was seen in the remaining pa-
tients histology (Table 1). Of the three patients who had
BAL washings available for analysis, one had fungal hy-
phae visualised in bronchial washings. Some had fruiting
bodies (conidiophores with conidia) of Aspergillus iden-
tified (Fig. 3), suggesting that the original infection with
Aspergillus occurred in an airspace or on an epithelial
surface, and subsequently was filled in with inflamma-
tory cells and Aspergillus hyphae.
Surgery
Nine patients underwent surgical resection of the lung
nodule. One patient had recurrent disease identified on
CT four years post operatively.
Discussion
In this, the largest published series of Aspergillus nod-
ules to date, the characteristics of 33 patients were
reviewed. These patients represent less than 10 % of the
cohort of patients with CPA cared for in the National
Aspergillosis Centre. However, this may be an under
representation of this presentation of CPA, as cases may
not be recognised, have negative Aspergillus IgG or pre-
cipitins, and/or not undergo biopsy to secure their diag-
nosis. However, recognition of nodules on CT scanning
of the thorax is becoming more common, as screening
for lung cancer is more frequently undertaken. Many
nodules identified on such screening scans are removed
or biopsied and do not reveal malignancy. Aspergillus
nodules are one such benign entity.
In those unable to undergo biopsy or resection be-
cause of poor respiratory reserve and a risk of
pneumothorax, empirical radiotherapy is sometimes
given for a ‘PET positive’ suspicious lesion. We have
seen at least 2 patients with chronic pulmonary asper-
gillosis in the area of radiotherapy, which we suspect,
but cannot prove, had an Aspergillus nodule that was
irradiated. We would therefore encourage clinical on-
cologists to consider the possibility of an Aspergillus
nodule before embarking on lung irradiation. The re-
sponse to radiotherapy may not be entirely problem-
atic however, as illustrated by a small series of CPA
patients explicitly treated with radiotherapy [14].
A number of other infections may also present with
pulmonary nodules, which may be difficult to distin-
guish on radiological features alone (Table 2). The
relative frequency of the differential diagnoses varies
substantially by geography. In endemic areas, other
fungal infections can present with persistent pulmon-
ary nodules of masses in apparently immunocompe-
tent persons. The appearance of such fungal
infections mimics malignancy and diagnosis is often
confirmed on biopsy. At one centre in Texas, USA 17
of 2,098 (0.6 %) persons presenting with pulmonary
nodule were ultimately diagnosed with histoplasmosis,
cryptococcosis or coccidiomycosis rather than malig-
nancy [15]. Another case series describes 27 cases of
Fig. 3 Biopsy demonstrating inflammation and necrosis and fungal
hyphae (low power) and fungal conidia (arrow) on high power
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fungal lung infection presenting with persistent lung
nodule or mass at 2 centres in Texas USA and Sao
Paulo Brazil respectively [16]. All cases were referred
for investigation of suspected malignancy. Diagnoses
included histoplasmosis (26 %), coccidioidomycosis
(22 %), cryptococcosis (22 %), aspergillosis (15 %),
blastomycosis (7 %), mucormycosis (4 %) and para-
coccidioidomycosis (4 %). Fourteen (52 %) of patients
had a past history of treated malignancy and 15
(56 %) were symptomatic at presentation. Thirteen
(48 %) of patients had cough, 7 (26 %) had chest pain
and 7 (26 %) weight loss. Increased PET avidity was
noted in all patients and all patients demonstrated
radiological improvement or resolution with appropri-
ate antifungal therapy.
The diagnosis of an Aspergillus nodule may be challen-
ging. Almost one third of patients did not have a positive
Aspergillus IgG, and only 12 % had detectable Aspergillus
fumigatus precipitins. Additionally the clinical features
may be non-specific, and similar to those in patients pre-
senting with malignant disease. In this study, cough alone
was the most common clinical finding. The demographics
of the patients diagnosed with Aspergillus nodules are also
similar to those diagnosed with malignant conditions of
the lung. Our centre previously reported on the PET im-
aging in patients with CPA [17]. In that series all of the
Table 2 Infectious differential diagnosis of pulmonary nodules
Cause of nodule/disease Underlying disease(s), geography CT characteristics Evolution
Aspergillus nodule Emphysema, asthma taking corticosteroids,
smoker. Not immunocompromised. Global
Single or multiple nodules. May affect
any lobe, although upper lobes most
common. Unlikely to be calcified
Slow to change. May cavitate
over many months.
Coccidioidal nodule None. Visit to, or inhabitant of,
endemic area.
Usually single, upper lobes.
Occasionally calcified.
Static over months or years.
Histoplasma nodule None. Visit to, or inhabitant of, endemic
area. May report specific exposure e.g
bat cave





Single or multiple. May be calcified.
>5 mm diameter.
Progressive
Pneumocystis jirovecii Usually immunocompromised patients,
HIV, steroids etc.
Single/multiple
Very rare cause of nodules in
immunocompetent host. Global
Nocardia spp. May mimic TB Single or multiple
Up to 1/3 cases occur in immunocompetent
hosts. Global
Dirofilariasis None. Mosquito borne zoonosis, travel to
South East Asia
Single or multiple nodules or cavities
Fig. 4 Current management algorithm for Aspergillus nodules. CXR = chest radiograph; CT = computed tomography; FU = follow up
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patients had positive PET imaging. Only a small number
of patients in this current series had PET scans available
for review, but all eight were positive with low-moderate
FDG uptake.
This study is limited by being a retrospective review.
Case finding was challenging, and despite a number of
sources being utilised to identify cases, it is possible
some cases were missed. However, this is the largest
series of Aspergillus nodules published to date, and the
only study to correlate radiology and histology findings
with clinical features and laboratory parameters, in
particular Aspergillus IgG. In patients with chronic cavi-
tary pulmonary aspergillosis, we found the ImmunoCap
Aspergillus IgG assay to be 96 % sensitive and 98 %
specific at a cutoff of 20 mg/L and 88 % sensitive and
100 % specific at the current manufacturer’s cutoff of
40 mg/L, compared to a healthy younger control popula-
tion [15]. So 69 to 81 % of patients in this series had
positive Aspergillus IgG serology, depending on the cut-
off used [18]. This further highlights this previously
lesser recognised manifestation of CPA.
The natural history of an Aspergillus nodule is not
known. We are unable to define how long they were
present before they came to medical attention, but we
suspect months. We do know that some of the nodules
remain stable off therapy for months or years after
diagnosis. In general we treated the symptomatic
patients, especially those with multiple lesions. Detec-
tion of Aspergillus in airways with culture or PCR also
influenced us to treat, especially in those with difficult
to control asthma or ABPA. We will report long term
outcomes in a subsequent paper. We summarise our
current approach to management in Fig. 4.
Conclusion
Pulmonary nodules are a less frequent manifestation of
chronic pulmonary aspergillosis in immune competent
patients. The natural history of these nodules is not yet
defined. In this series, cough alone was a common pre-
senting symptom. It may be difficult to distinguish As-
pergillus nodules from other pathology on CT findings
alone, and PET imaging would seem to be non discrim-
inatory. Additionally, a significant proportion of these
patients do not have a detectable Aspergillus IgG, mean-
ing biopsy is necessary to exclude malignant disease.
However, chronic pulmonary aspergillosis, should be a
differential diagnosis in patients presenting with single
or multiple pulmonary nodules.
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